Trial · NCT00624468
Results by group90
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 90
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in Retinal Nerve Fiber Layer (RNFL) Thickness in the Affected Eye at Last Observed Value (LOV) | Placebo: Double-blind Period | Baseline (n = 17, 17) | 103.893 | Standard Deviation 17.271 | micrometer |
| Change From Baseline in Retinal Nerve Fiber Layer (RNFL) Thickness in the Affected Eye at Last Observed Value (LOV) | Atacicept: Double-blind Period | Baseline (n = 17, 17) | 104.170 | Standard Deviation 8.832 | micrometer |
| Change From Baseline in Retinal Nerve Fiber Layer (RNFL) Thickness in the Affected Eye at Last Observed Value (LOV) | Placebo: Double-blind Period | Change at LOV (n = 16, 15) | -17.317 | Standard Deviation 15.158 | micrometer |
| Change From Baseline in Retinal Nerve Fiber Layer (RNFL) Thickness in the Affected Eye at Last Observed Value (LOV) | Atacicept: Double-blind Period | Change at LOV (n = 16, 15) | -8.636 | Standard Deviation 10.056 | micrometer |
| Difference in Retinal Nerve Fibre Layer (RNFL) Thickness Between the Affected Eye and Fellow Eye | Placebo: Double-blind Period | Change at Week 12 (n = 13, 13) | -14 | Standard Error 4 | micrometer |
| Difference in Retinal Nerve Fibre Layer (RNFL) Thickness Between the Affected Eye and Fellow Eye | Atacicept: Double-blind Period | Change at Week 12 (n = 13, 13) | -7.9 | Standard Error 1.5 | micrometer |
| Difference in Retinal Nerve Fibre Layer (RNFL) Thickness Between the Affected Eye and Fellow Eye | Placebo: Double-blind Period | Change at Week 24 (n = 4, 5) | -7 | Standard Error 6.9 | micrometer |
| Difference in Retinal Nerve Fibre Layer (RNFL) Thickness Between the Affected Eye and Fellow Eye | Atacicept: Double-blind Period | Change at Week 24 (n = 4, 5) | -10.6 | Standard Error 3.7 | micrometer |
| Difference in Retinal Nerve Fibre Layer (RNFL) Thickness Between the Affected Eye and Fellow Eye | Placebo: Double-blind Period | Change at Week 36 (n = 3, 4) | -7.5 | Standard Error 8.8 | micrometer |
| Difference in Retinal Nerve Fibre Layer (RNFL) Thickness Between the Affected Eye and Fellow Eye | Atacicept: Double-blind Period | Change at Week 36 (n = 3, 4) | -9.4 | Standard Error 6.6 | micrometer |
| Change From Baseline in Retinal Nerve Fiber Layer (RNFL) Thickness in the Affected Eye at Weeks 12 and 24 | Placebo: Double-blind Period | Baseline (n=17, 17) | 103.893 | Standard Deviation 17.271 | micrometer |
| Change From Baseline in Retinal Nerve Fiber Layer (RNFL) Thickness in the Affected Eye at Weeks 12 and 24 | Atacicept: Double-blind Period | Baseline (n=17, 17) | 104.170 | Standard Deviation 8.832 | micrometer |
| Change From Baseline in Retinal Nerve Fiber Layer (RNFL) Thickness in the Affected Eye at Weeks 12 and 24 | Placebo: Double-blind Period | Change at Week 12 (n = 13, 13) | -17.036 | Standard Deviation 13.919 | micrometer |
| Change From Baseline in Retinal Nerve Fiber Layer (RNFL) Thickness in the Affected Eye at Weeks 12 and 24 | Atacicept: Double-blind Period | Change at Week 12 (n = 13, 13) | -9.356 | Standard Deviation 9.532 | micrometer |
| Change From Baseline in Retinal Nerve Fiber Layer (RNFL) Thickness in the Affected Eye at Weeks 12 and 24 | Placebo: Double-blind Period | Change at Week 24 (n = 4, 5) | -17.815 | Standard Deviation 16.505 | micrometer |
| Change From Baseline in Retinal Nerve Fiber Layer (RNFL) Thickness in the Affected Eye at Weeks 12 and 24 | Atacicept: Double-blind Period | Change at Week 24 (n = 4, 5) | -11.234 | Standard Deviation 14.230 | micrometer |
| Change From Baseline in Macular Thickness at 3 Millimeter (mm) Around Fovea in the Affected Eye at Weeks 12, 24 and 36 | Placebo: Double-blind Period | Baseline (n = 17, 17) | 1054.4 | Standard Deviation 76.5 | micrometer |
| Change From Baseline in Macular Thickness at 3 Millimeter (mm) Around Fovea in the Affected Eye at Weeks 12, 24 and 36 | Atacicept: Double-blind Period | Baseline (n = 17, 17) | 1070.6 | Standard Deviation 72.7 | micrometer |
| Change From Baseline in Macular Thickness at 3 Millimeter (mm) Around Fovea in the Affected Eye at Weeks 12, 24 and 36 | Placebo: Double-blind Period | Change at Week 12 (n = 13, 13) | -29.3 | Standard Deviation 34.4 | micrometer |
| Change From Baseline in Macular Thickness at 3 Millimeter (mm) Around Fovea in the Affected Eye at Weeks 12, 24 and 36 | Atacicept: Double-blind Period | Change at Week 12 (n = 13, 13) | -34.0 | Standard Deviation 21.8 | micrometer |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00624468/results